Florida Nonprofit Alliance Symposium
The first-ever Florida Nonprofit Alliance Symposium will be held at the TCC Capitol (located in the same building as The Mary Brogan Museum of Art and Science) on Wednesday January 15 from 10am to 2pm. The keynote speaker is Florida’?s chief nonprofit regulator, Commissioner of Agriculture and Consumer Services Adam Putnam. He will unveil new legislation impacting the nonprofit sector at the event. Robert Egger, a nationally-renowned nonprofit author and activist will open the meeting; expert presenters will engage Symposium attendees on the 2014 Legislative Session, share new research from the National Council of Nonprofits, and work together to set state-wide priorities for legislative action. It should be well worth the $50 registration fee (which includes lunch).
The Florida Nonprofit Alliance is the only nationally recognized statewide association of nonprofit organizations in Florida. Created to fill the advocacy void in our State, it has a Tallahassee representative watching out for your interests. I hope you’ll support its work to advance Florida’s nonprofit sector and consider joining us in at the Capitol Center on the 15th!
To register for the Florida Nonprofit Alliance Symposium, visit the FNA website at: http://www.flnonprofits.org/events/event_details.asp?id=384456
All my best…………TGG
Online Expert Advice for Clinicians Treating Hepatitis C Now Available at HCVguidelines.org
Today, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), in collaboration with the International Antiviral Society- USA (IAS-USA), announced the launch of a new website, HCVguidelines.org, that will offer up-to- date guidance for the treatment of hepatitis C virus (HCV) infection.
It is estimated that between 3 and 4 million Americans are infected with HCV and have chronic liver disease as a result. The most recent generation of direct-acting antivirals has the potential to cure most patients with HCV. However, the rapid pace of drug development has left medical providers and insurance companies unsure what the optimal treatments are. The guidance provided through HCVguidelines.org will assist clinicians in using these and other treatments in the care of their patients.
HCVguidelines.org is the result of an ongoing collaboration between the two medical professional societies and IAS-USA. A panel of 26 liver disease and infectious diseases specialists and a patient advocate developed evidenced-based, consensus recommendations for the screening, treatment and management of patients with HCV. This guidance will be made available for health care providers who treat the disease and others who need updated information on the best practices. The site will be updated regularly to keep pace with improved diagnostic tools and new drug options as they meet Food and Drug Administration approval.
“Recent changes in HCV testing guidelines have led to the diagnosis of increasing numbers of patients who were previously unaware of their infection. The guidance provided through HCVguidelines.org comes at a critical time as more and more of these patients seek treatment that has the potential to effectively ‘cure’ them,” said Adrian Di Bisceglie, MD, FACP, president of AASLD.
“In just the past three months, two new medications became available for treating HCV that hold a great deal of promise for patients living with this disease, and more are expected.
HCVguidelines.org provides physicians with the latest information and informed guidance on the available treatment options based on a rigorous review of data,” said Barbara Murray, MD, IDSA, president of IDSA.
“An estimated 3-4 million Americans are infected with HCV and are at risk of progressing to chronic liver disease as a result,” said Michael Saag, MD, FIDSA, a member of the Board of Directors of the IAS-USA and a co-chair of the guidance panel. He added, “The presence of a readily available, frequently updated guidance document is a great service to providers and their patients, who will benefit from modern treatments that result in cure of HCV up to 95% of the time.”
About the AASLD
AASLD is a medical subspecialty society representing clinicians and researchers in liver disease. The work of our members has laid the foundation for the development of drugs used to treat patients with viral hepatitis. Access to care and support of liver disease research are at the center of AASLD’s advocacy efforts.
AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists and has grown to an international society responsible for all aspects of hepatology.
Press releases and additional information about AASLD are available online at www.aasld.org
About IDSA
The Infectious Diseases Society of America (IDSA) is an organization of physicians, scientists, and other health care professionals dedicated to promoting health through excellence in infectious diseases research, education, prevention, and patient care. The Society, which has nearly 10,000 members, was founded in 1963 and is based in Arlington, VA. For more information, see www.idsociety.org.
Visit www.idsociety.org/HCV/ to access IDSA’s extensive collection of resources on hepatitis C, including the Society’s Core Curriculum for HCV at www.idsociety.org/HCV_Curriculum/#Introduction.
About IAS-USA
The International Antiviral Society – USA (IAS-USA) serves as acollaborating partner for the AASLD/IDSA Hepatitis C Virus (HCV) Guidance and is responsible for providing expertise and administrative support to HCV Guidance Panel members and processes. A representative from the IAS-USA serves as a co-chair of the HCV Guidance Panel. For more information, see http://iasusa.org
March 12, 2015
| House 2015 Session Appropriations Overview
|
The House Rules, Calendar & Ethics Committee proposed its special amendment deadlines & procedures for this year's appropriations bills to be adopted on the floor March 17, 2015. Friday, March 20, 2015 - 8 a.m. The Appropriations Committee will make electronically available the proposed General Appropriations bill and related implementing and conforming bills to be considered at its meeting on Wednesday, March 25, 2015. Monday, March 23, 2015 - 4 p.m. All main amendments for the proposed General Appropriations bill and related implementing and conforming bills must be filed for the Appropriations Committee meeting on Wednesday, March 25,2015. Amendments must be filed with the Appropriations Committee. Monday, March 23, 2015 - 8 p.m. Packages of amendments will be made available. Tuesday, March 24, 2015 - 12 p.m. All amendments to the amendments and substitute amendments must be filed with the Appropriations Committee. Wednesday, March 25, 2015 - TBD The Appropriations Committee will meet. Friday, March 27, 2015 - 8 a.m. The General Appropriations bill, implementing bill, and conforming bills, as amended, will be filed, published, and made electronically available. Monday, March 30, 2015 - 4 p.m. All requests for main floor amendments for the General Appropriations bill must be submitted to the Appropriations Committee. All requests for main floor amendments for related implementing and conforming bills must be approved for filing. Monday, March 30, 2015 - 8 p.m. Packages of amendments will be made available. Tuesday, March 31, 2015 - 12 p.m. All requests for amendments to floor amendments and substitute amendments to floor amendments for the General Appropriations bill must be submitted to the Appropriations Committee. All requests for amendments to floor amendments and substitute amendments to floor amendments for related implementing and conforming bills must be approved for filing. Wednesday, April 1, 2015 - TBD Second reading Thursday, April 2, 2015 - TBD Third reading ========================= To change your email alert settings or unsubscribe go to http://apps.lobbytools.com/tools/my.cfm?a=alerts Please be advised, replies to this email will not be received. Please use the Ask For Help Feature in the Help and Training Tab to contact a Lobbytools Customer Support Representative. (C) COPYRIGHT 2015 LOBBYTOOLS, INC. ALL RIGHTS RESERVED. For additional usage or distribution permissions, contact sales@lobbytools.com (850) 915-0100 x3 http://www.lobbytools.com/
| |||||||||||||||||||||||
